A Study Assessing the Safety and Efficacy of Subcutaneous RoActemra/Actemra Alone or in Combination With Non-biologic Antirheumatics in Rhuematoid Arthritis Patients in Latin America With Inadequate Response to Non-biologic Antirheumatic Drugs.

NCT02011334 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

285

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis

Interventions

DRUG: tocilizumab [RoActemra/Actemra]

Sponsor

Hoffmann-La Roche